Top

International Journal of Clinical Oncology

Published in:

01-01-2019 | Original Article

Does tumour effraction during robotic partial nephrectomy have any impact on recurrence?

Authors: Zine-Eddine Khene, Benoit Peyronnet, Benjamin Pradère, Corentin Robert, Anna Goujon, Solène-Florence Kammerer-Jacquet, Grégory Verhoest, Nathalie Rioux-Leclercq, Romain Mathieu, Karim Bensalah

Published in: International Journal of Clinical Oncology | Issue 1/2019

Abstract

Objective

To evaluate the impact of accidental surgical incision into the tumour (ASIT) on oncological outcomes in patients undergoing RPN for a malignant tumour.

Materials and methods

A retrospective review of our prospectively maintained database was performed to identify all patients who underwent RPN for a localized RCC between June 2010 and July 2016. We stratified our cohort into two groups according to the presence of an ASIT. Perioperative data were compared between the two groups. Logistic regression analyses were used to assess the variables associated with ASIT. Recurrence-free survival was estimated using the Kaplan–Meier method and compared between groups with the log-rank test.

Results

A total of 234 patients were identified. 32 (14%) ASIT were observed. Patients’ characteristics were similar in the two groups. Most of intraoperative outcomes were comparable between the two groups, but patients in the ASIT group had greater EBL (475 vs. 300 mL; p = 0.01). In multivariate analysis, tumour size (p = 0.02), RENAL score (p = 0.02), EBL (p = 0.05) and low surgeon experience (p = 0.03) were all predictive factors of ASIT. 15 (6%) of recurrences were observed over a median follow-up of 36 months. There was no difference in recurrence-free survival between the two groups (p = 0.57).

Conclusions

In our experience, accidental surgical incision into the tumour during RPN was a common event that did not appear to compromise oncological outcome.

Campbell S, Uzzo RG, Allaf ME et al (2017) Renal mass and localized renal cancer: AUA guideline. J Urol [Internet] 198:520–529

Kunath F, Schmidt S, Krabbe L-M et al (2017) Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. In: The Cochrane Collaboration (ed) Cochrane database of systematic reviews [Internet]. Wiley, Chichester. https://doi.org/10.1002/14651858.CD012045.pub2 CrossRef

Schiavina R, Mari A, Antonelli A et al (2015) A snapshot of nephron-sparing surgery in Italy: a prospective, multicenter report on clinical and perioperative outcomes (the RECORd 1 project). Eur J Surg Oncol 41(3):346–352CrossRefPubMed

Peyronnet B, Seisen T, Oger E, Vaessen C et al (2016) Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol 23(13):4277–4283CrossRefPubMed

Ficarra V, Minervini A, Antonelli A et al (2014) A multicentre matched-pair analysis comparing robot-assisted versus open partial nephrectomy: perioperative results of RAPN vs OPN. BJU Int 113(6):936–941CrossRefPubMed

Novara G, La Falce S, Kungulli A et al (2016) Robot-assisted partial nephrectomy. Int J Surg 36:554–559CrossRefPubMed

Ficarra V, Righetti R, Pilloni S et al (2002) Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 41(2):190–198CrossRefPubMed

Tanaka T, Terai Y, Maeda K et al (2017) Intraperitoneal cytology after laparoscopic hysterectomy in patients with endometrial cancer: a retrospective observational study. Medicine 96(27):e7502CrossRefPubMedPubMedCentral

Paolucci V, Schaeff B, Schneider M et al (1999) Tumor seeding following laparoscopy: international survey. World J Surg 23(10):989–995CrossRefPubMed

10.

Benway BM, Wang AJ, Cabello JM et al (2009) Robotic partial nephrectomy with sliding-clip renorrhaphy: technique and outcomes. Eur Urol 55(3):592–599CrossRefPubMed

11.

Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182(3):844–853CrossRefPubMed

12.

Davidiuk AJ, Parker AS, Thomas CS et al (2014) Mayo adhesive probability score: an accurate image-based scoring system to predict adherent perinephric fat in partial nephrectomy. Eur Urol 66(6):1165–1171CrossRefPubMed

13.

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral

14.

Shah PH, Moreira DM, Okhunov Z et al (2016) Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol 196(2):327–334CrossRefPubMed

15.

Autorino R, Porpiglia F, Dasgupta P et al (2017) Precision surgery and genitourinary cancers. Eur J Surg Oncol 43(5):893–908CrossRefPubMed

16.

Sutherland SE, Resnick MI, Maclennan GT et al (2002) Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol 167(1):61–64CrossRefPubMed

17.

Parker WP, Cheville JC, Frank I et al (2017) Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol 71(4):665–673CrossRefPubMed

18.

Bretheau D, Lechevallier E, de Fromont M et al (1995) Prognostic value of nuclear grade of renal cell carcinoma. Cancer 76(12):2543–2549CrossRefPubMed

19.

Maurice MJ, Zhu H, Kim S et al (2016) Survival after partial and radical nephrectomy for high-risk disease: a propensity-matched comparison. Can Urol Assoc J 10(9–10):E282–E289CrossRefPubMedPubMedCentral

20.

Becker A, Hickmann D, Hansen J et al (2016) Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma—impact on prognosis. Eur J Surg Oncol 42(3):419–425CrossRefPubMed

21.

Pahernik S, Ziegler S, Roos F et al (2007) Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol 178(2):414–417 (discussion 416–417) CrossRefPubMed

22.

Frank I, Blute ML, Cheville JC et al (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170(6 Pt 1):2217–2220CrossRefPubMed

23.

Bhindi B, Lohse CM, Mason RJ et al (2017) Are we using the best tumor size cut-points for renal cell carcinoma staging? Urology 109:121–126

24.

Kwon EO, Carver BS, Snyder ME et al (2007) Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours. BJU Int 99(2):286–289CrossRefPubMed

25.

Bensalah K, Pantuck AJ, Rioux-Leclercq N et al (2010) Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol 57(3):466–471CrossRefPubMed

26.

Yossepowitch O, Thompson RH, Leibovich BC et al (2008) Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 179(6):2158–2163CrossRefPubMedPubMedCentral

27.

Klein EA, Bianco FJ, Serio AM et al (2008) Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 179(6):2212–2216 (discussion 2216–2217) CrossRefPubMedPubMedCentral

28.

Rolevich A, Minich A, Nabebina T et al (2016) Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. Cent Eur J Urol 69(2):170–177

29.

Khandwala YS, Jeong IG, Kim JH et al (2017) The impact of surgeon volume on perioperative outcomes and cost for patients receiving robotic partial nephrectomy. J Endourol [Internet]. https://doi.org/10.1089/end.2017.0207 CrossRef

Title: Does tumour effraction during robotic partial nephrectomy have any impact on recurrence?
Authors: Zine-Eddine Khene
Benoit Peyronnet
Benjamin Pradère
Corentin Robert
Anna Goujon
Solène-Florence Kammerer-Jacquet
Grégory Verhoest
Nathalie Rioux-Leclercq
Romain Mathieu
Karim Bensalah
Publication date: 01-01-2019
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1331-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Fertility preservation for female cancer patients

Diagnostic accuracy of magnetic resonance imaging and computed tomography for lateral lymph node metastasis in rectal cancer: a systematic review and meta-analysis

Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma

Long-term influence of adjuvant breast radiotherapy on cognitive function in breast cancer patients treated with conservation therapy

Preoperative predictors of difficult hypopharyngeal exposure by retractor for transoral robotic surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer